Sarepta Plots Multi-Study Label Expansion For Elevidys To Eventually Cover Nearly All DMD Population
Executive Summary
Studies supporting label expansion already are under way, with more targeting those currently ineligible, including boys with pre-existing antibodies, set to begin later this year, after the initial accelerated approval only allowed use in four- and five-year old patients.